Blog
RSS FeedPosted by Michael Wonder on 22 May 2025
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the ...
Posted by Michael Wonder on 21 May 2025
New weekly treatment option approved for patients with haemophilia B
21 May 2025 - Final draft guidance published today recommends marstacimab (Hympavzi; Pfizer) for treating severe haemophilia B in patients ...
Posted by Michael Wonder on 15 May 2025
Deal agreed for continued access to life-changing treatment for rare inherited disease
14 May 2025 - NICE is consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2, ...
Posted by Michael Wonder on 15 May 2025
Health inequalities - an update to NICE’s methods for health technology evaluation
14 May 2025 - Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in ...
Posted by Michael Wonder on 12 May 2025
Erdafitinib for the treatment of patients with unresectable or metastatic urothelial cancer with an FGFR3 alteration after a PD-1 or PD-L1 inhibitor
12 May 2025 - Erdafitinib is recommended as an option for the treatment of adults with unresectable or metastatic urothelial cancer ...
Posted by Michael Wonder on 09 May 2025
Adagrasib for previously treated patients with advanced KRAS G12C mutation positive non-small-cell lung cancer
9 May 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 May 2025
Osimertinib mesylate in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy for patients with advanced EGFR mutation positive non-small-cell lung cancer (final guidance)
8 May 2025 - Osimertinib mesylate, when used in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy, is recommended as an ...
Posted by Michael Wonder on 08 May 2025
Brentuximab vedotin in combination with chemotherapy for the treatment of patients with stage 3 or 4 CD30 positive Hodgkin lymphoma
7 May 2025 - Brentuximab vedotin, when used in combination with doxorubicin hydrochloride, dacarbazine and vinblastine sulphate is recommended as an ...
Posted by Michael Wonder on 07 May 2025
Omaveloxolone for the treatment of patients with Friedreich’s ataxia
6 May 2025 - NICE is unable to make a recommendation on the use of omaveloxolone (Skyclarys) for the treatment of ...
Posted by Michael Wonder on 03 May 2025
Vimkunya vaccine approved to prevent disease caused by the chikungunya virus in people 12 years of age and older
1 May 2025 - The MHRA has today approved a vaccine (Vimkunya) used to prevent disease caused by the chikungunya virus ...
Posted by Michael Wonder on 01 May 2025
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age ...
Posted by Michael Wonder on 01 May 2025
MHRA authorises cancer treatment variation with an administration time of 3–5 minutes
30 April 2025 - The MHRA has today approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), ...
Posted by Michael Wonder on 27 Apr 2025
Dupilumab for the treatment of patients with moderate to severe chronic obstructive pulmonary disease
24 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 27 Apr 2025
MHRA approves first UK treatment for Friedreich’s ataxia, omaveloxolone
23 April 2025 - The MHRA) has today approved omaveloxolone (Skyclarys), the first treatment for patients aged 16 and over, in ...
Posted by Michael Wonder on 27 Apr 2025
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms
22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...